Senescent endothelial cells are predisposed to SARS-CoV-2 infection and subsequent endothelial dysfunction.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
25 07 2022
Historique:
received: 03 03 2022
accepted: 01 07 2022
entrez: 25 7 2022
pubmed: 26 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

The coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains to spread worldwide. COVID-19 is characterized by the striking high mortality in elderly; however, its mechanistic insights remain unclear. Systemic thrombosis has been highlighted in the pathogenesis of COVID-19, and lung microangiopathy in association with endothelial cells (ECs) injury has been reported by post-mortem analysis of the lungs. Here, we experimentally investigated the SARS-CoV-2 infection in cultured human ECs, and performed a comparative analysis for post-infection molecular events using early passage and replicative senescent ECs. We found that; (1) SARS-CoV-2 infects ECs but does not replicate and disappears in 72 hours without causing severe cell damage, (2) Senescent ECs are highly susceptible to SARS-CoV-2 infection, (3) SARS-CoV-2 infection alters various genes expression, which could cause EC dysfunctions, (4) More genes expression is affected in senescent ECs by SARS-CoV-2 infection than in early passage ECs, which might causes further exacerbated dysfunction in senescent ECs. These data suggest that sustained EC dysfunctions due to SARS-CoV-2 infection may contribute to the microangiopathy in the lungs, leading to deteriorated inflammation and thrombosis in COVID-19. Our data also suggest a possible causative role of EC senescence in the aggravated disease in elder COVID-19 patients.

Identifiants

pubmed: 35879338
doi: 10.1038/s41598-022-15976-z
pii: 10.1038/s41598-022-15976-z
pmc: PMC9314328
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11855

Informations de copyright

© 2022. The Author(s).

Références

Science. 2021 Jul 30;373(6554):
pubmed: 34326210
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Circ Res. 2021 Apr 30;128(9):1323-1326
pubmed: 33784827
BMC Cardiovasc Disord. 2015 Oct 19;15:130
pubmed: 26481314
Sci Rep. 2021 Jul 16;11(1):14608
pubmed: 34272458
mBio. 2022 Jun 28;13(3):e0036422
pubmed: 35467423
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Virol. 2000 Jan;74(1):42-8
pubmed: 10590089
Virology. 2005 Jul 20;338(1):53-60
pubmed: 15936793
Science. 2016 Oct 28;354(6311):472-477
pubmed: 27789842
Ageing Res Rev. 2021 Jul;68:101332
pubmed: 33753287
Signal Transduct Target Ther. 2022 Mar 11;7(1):83
pubmed: 35277473
mBio. 2020 Dec 11;11(6):
pubmed: 33310781
Arterioscler Thromb Vasc Biol. 2018 Jun;38(6):e90-e95
pubmed: 29793992
Nature. 2011 Nov 02;479(7372):232-6
pubmed: 22048312
Cell. 2017 Mar 23;169(1):132-147.e16
pubmed: 28340339
J Biol Chem. 2021 Jan-Jun;296:100306
pubmed: 33476648
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Nat Med. 2017 Jun;23(6):775-781
pubmed: 28436958
Kidney Int. 2020 Aug;98(2):505-506
pubmed: 32446936
Clin Transl Immunology. 2021 Oct 24;10(10):e1350
pubmed: 34721846
Virol J. 2009 Dec 07;6:217
pubmed: 19968865
Science. 2021 Jul 16;373(6552):
pubmed: 34103349
Nat Med. 2018 Aug;24(8):1246-1256
pubmed: 29988130
Front Cell Infect Microbiol. 2021 Jul 06;11:701278
pubmed: 34307198
Nat Commun. 2020 Jan 24;11(1):481
pubmed: 31980643
Nat Rev Rheumatol. 2020 Oct;16(10):581-589
pubmed: 32733003
Lancet. 2020 May 30;395(10238):e99
pubmed: 32442529
J Virol. 2006 Jul;80(14):6964-72
pubmed: 16809302
Cells. 2021 Jun 07;10(6):
pubmed: 34200372
Viruses. 2020 Apr 26;12(5):
pubmed: 32357558
Int J Mol Sci. 2021 Jan 28;22(3):
pubmed: 33525651
Basic Res Cardiol. 2021 Jul 5;116(1):42
pubmed: 34224022
Mod Pathol. 2020 Nov;33(11):2104-2114
pubmed: 32561849
Nature. 2020 Sep;585(7823):16-17
pubmed: 32860026
Viruses. 2011 Jun;3(6):920-40
pubmed: 21994762
J Clin Microbiol. 2001 Jan;39(1):196-200
pubmed: 11136770
Heliyon. 2021 Feb 02;7(2):e06187
pubmed: 33644468
Nature. 2016 Feb 11;530(7589):184-9
pubmed: 26840489
Nat Med. 2020 Apr;26(4):502-505
pubmed: 32284613

Auteurs

Ryota Urata (R)

Department of Cardiology, Kyoto Prefectural University of Medicine, 465 Kajii, Kawaramachi-Hirokoji, Kamigyo, Kyoto, 602-8566, Japan.

Koji Ikeda (K)

Department of Cardiology, Kyoto Prefectural University of Medicine, 465 Kajii, Kawaramachi-Hirokoji, Kamigyo, Kyoto, 602-8566, Japan. ikedak@koto.kpu-m.ac.jp.
Department of Epidemiology for Longevity and Regional Health, Kyoto Prefectural University of Medicine, 465 Kajii, Kawaramachi-Hirokoji, Kamigyo, Kyoto, 602-8566, Japan. ikedak@koto.kpu-m.ac.jp.

Ekura Yamazaki (E)

Department of Cardiology, Kyoto Prefectural University of Medicine, 465 Kajii, Kawaramachi-Hirokoji, Kamigyo, Kyoto, 602-8566, Japan.

Daisuke Ueno (D)

Department of Cardiology, Kyoto Prefectural University of Medicine, 465 Kajii, Kawaramachi-Hirokoji, Kamigyo, Kyoto, 602-8566, Japan.

Akiko Katayama (A)

Department of Cardiology, Kyoto Prefectural University of Medicine, 465 Kajii, Kawaramachi-Hirokoji, Kamigyo, Kyoto, 602-8566, Japan.

Masaharu Shin-Ya (M)

Department of Immunology, Kyoto Prefectural University of Medicine, 465 Kajii, Kawaramachi-Hirokoji, Kamigyo, Kyoto, 602-8566, Japan.

Eriko Ohgitani (E)

Department of Immunology, Kyoto Prefectural University of Medicine, 465 Kajii, Kawaramachi-Hirokoji, Kamigyo, Kyoto, 602-8566, Japan.

Osam Mazda (O)

Department of Immunology, Kyoto Prefectural University of Medicine, 465 Kajii, Kawaramachi-Hirokoji, Kamigyo, Kyoto, 602-8566, Japan.

Satoaki Matoba (S)

Department of Cardiology, Kyoto Prefectural University of Medicine, 465 Kajii, Kawaramachi-Hirokoji, Kamigyo, Kyoto, 602-8566, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH